Last update 20 Mar 2025

DYP-688

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
GNA11 x GNAQ
Action
inhibitors
Mechanism
GNA11 inhibitors(G protein subunit alpha 11 inhibitors), GNAQ inhibitors(G protein subunit alpha q inhibitors)
Therapeutic Areas
NeoplasmsEye DiseasesSkin and Musculoskeletal Diseases+ [1]
Active Indication
Uveal Melanoma
Inactive Indication-
Originator Organization
Novartis Pharma AG
Active Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with DYP-688
NCT05415072
/ RecruitingPhase 1/2
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
100 Clinical Results associated with DYP-688
Login to view more data
100 Translational Medicine associated with DYP-688
Login to view more data
100 Patents (Medical) associated with DYP-688
Login to view more data
1
Literatures (Medical) associated with DYP-688
01 Feb 2025Journal of Pharmacokinetics and Pharmacodynamics
QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life
100 Deals associated with DYP-688
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uveal MelanomaPhase 2
Germany
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
04 Jul 2022
Uveal MelanomaPhase 2
Spain
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
04 Jul 2022
Uveal MelanomaPhase 2
Australia
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
04 Jul 2022
Uveal MelanomaPhase 2
United States
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
04 Jul 2022
Uveal MelanomaPhase 2
Netherlands
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
04 Jul 2022
Uveal MelanomaPhase 2
France
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
04 Jul 2022
Uveal MelanomaPhase 2
Switzerland
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
04 Jul 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free